Lv5
868 积分 2025-08-07 加入
JSH practical guidelines for hematological malignancies, 2023 III. Myeloma 1. Multiple myeloma (MM)
1天前
已完结
Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM)
12天前
已完结
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
16天前
已完结
Peripheral and Cranial Neuropathies Following CAR-T Cell Therapy for Multiple Myeloma: A Case Series (S16.006)
16天前
已关闭
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
18天前
已完结
First-line Therapy in Newly Diagnosed Multiple Myeloma
24天前
已完结
Hallmarks of T-cell exhaustion and antigen experience are absent in multiple myeloma from diagnosis to maintenance therapy
26天前
已完结
Teclistamab in Relapsed or Refractory Multiple Myeloma
1个月前
已关闭
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study
1个月前
已完结
皖公网安备34019202002308
